Page last updated: 2024-11-06

u 88204

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 88204: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72346
CHEMBL ID289969
SCHEMBL ID14440008
MeSH IDM0195697

Synonyms (15)

Synonym
bdbm2291
2-[4-(1h-indol-2-ylcarbonyl)piperazin-1-yl]-n-(propan-2-yl)pyridin-3-amine
1h-indol-2-yl-[4-[3-(isopropylamino)-2-pyridyl]piperazin-1-yl]methanone
148692-46-0
u-88204
1-(indolyl-2-carbonyl)-4-[3-[(1-methylethyl)amino]pyridyl]piperazine
u-88204e
u 88204
CHEMBL289969
piperazine, 1-(1h-indol-2-ylcarbonyl)-4-(3-((1-methylethyl)amino)-2-pyridinyl)-
136816-76-7
1-(3-(1-isopropylamino)-2-pyridinyl)-4-((1-h-indol-2-yl)carbonyl)piperazine
SCHEMBL14440008
DTXSID00159941
methanone, 1h-indol-2-yl[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)1.20000.00060.91418.3200AID1795382
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)1.20000.00011.076810.0000AID197807
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1ED500.30000.00020.99359.8000AID1594865
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID104244Cytotoxic concentration against MT-2 cells1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID1594865Inhibition of HIV1 3B reverse transcriptase infected in human PBMC cells after 4 days2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID81442Inhibition of HIV-1 D34 replication in human peripheral blood mononuclear cells.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID198593In vitro inhibition of HIV-1 reverse transcriptase at 100 uM1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID153102Cytotoxic concentration against PBMC cells1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID197807In vitro inhibition of HIV-1 reverse transcriptase1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID81443Inhibition of HIV-1 IIIB replication in MT2 (human lymphocyte) cells.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID1795382HIV-1 RT Assay from Article 10.1021/jm00062a027: \\Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-c1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]